Premium
Pyrazolopyrimidines: Potent Inhibitors Targeting the Capsid of Rhino‐ and Enteroviruses
Author(s) -
Makarov Vadim A.,
Braun Heike,
Richter Martina,
Riabova Olga B.,
Kirchmair Johannes,
Kazakova Elena S.,
Seidel Nora,
Wutzler Peter,
Schmidtke Michaela
Publication year - 2015
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201500304
Subject(s) - capsid , coxsackievirus , myocarditis , pharmacodynamics , pharmacology , enterovirus , virology , drug , antiviral drug , medicine , pharmacokinetics , chemistry , virus
There are currently no drugs available for the treatment of enterovirus (EV)‐induced acute and chronic diseases such as the common cold, meningitis, encephalitis, pneumonia, and myocarditis with or without consecutive dilated cardiomyopathy. Here, we report the discovery and characterization of pyrazolopyrimidines, a well‐tolerated and potent class of novel EV inhibitors. The compounds inhibit the replication of a broad spectrum of EV in vitro with IC 50 values between 0.04 and 0.64 μ M for viruses resistant to pleconaril, a known capsid‐binding inhibitor, without affecting cytochrome P450 enzyme activity. Using virological and genetics methods, the viral capsid was identified as the target of the most promising, orally bioavailable compound 3‐(4‐trifluoromethylphenyl)amino‐6‐phenylpyrazolo[3,4‐ d ]pyrimidine‐4‐amine (OBR‐5‐340). Its prophylactic as well as therapeutic application was proved for coxsackievirus B3‐induced chronic myocarditis in mice. The favorable pharmacokinetic, toxicological, and pharmacodynamics profile in mice renders OBR‐5‐340 a highly promising drug candidate, and the regulatory nonclinical program is ongoing.